Medicine and HealthNature Communications
Engineered ACE2 receptor therapy overcomes mutational escape of SARS-CoV-2
Y. Higuchi, T. Suzuki, et al.
This groundbreaking research, conducted by Yusuke Higuchi and colleagues, presents an engineered high-affinity human ACE2 receptor that neutralizes SARS-CoV-2 effectively, showcasing its potential to combat the virus and prevent escape mutants. The study demonstrates significant protection against the virus in hamsters, suggesting a promising therapeutic approach.
Related Publications
Explore these studies to deepen your understanding
Adjacent work that informs or extends this paper's methodology and findings.
Medicine and Health
Molecular interaction and inhibition of SARS-CoV-2 binding to the ACE2 receptor
J. Yang, S. J. L. Petitjean, et al.
Medicine and Health
Broad host range of SARS-CoV-2 and the molecular basis for SARS-CoV-2 binding to cat ACE2
L. Wu, Q. Chen, et al.
Medicine and Health
Parallel profiling of antigenicity alteration and immune escape of SARS-CoV-2 Omicron and other variants
C. Sun, Y. Kang, et al.
Medicine and Health
Risk factors for and pregnancy outcomes after SARS-CoV-2 in pregnancy according to disease severity: A nationwide cohort study with validation of the SARS-CoV-2 diagnosis of Nordic Federation of Societies of Obstetrics and Gynecology (NFOG)
A. J. M. Aabakke, T. G. Petersen, et al.
